Chinese ADC Developers Catch Up with Global Players In Advancing Key Payloads
Multiple Active Players
Executive Summary
Chinese pharma firms led by Kelun are moving fast to develop the next-generation of cytotoxic "warheads," a key component of antibody-drug conjugates, disclosed company executives at conference in Suzhou.
You may also be interested in...
New Results Provide Glimpse Into BlissBio's Enhertu Challenger In HER2-Low Breast Cancer
China's BlissBio has unveiled new clinical results for its HER2-targeting ADC BB-1701 in HER2-low breast cancer, which showed “promising” preliminary efficacy and "manageable" safety, in a glimpse into the Enhertu challenger's potential.
BeiGene Joins Antibody-Drug Conjugate Stampede With DualityBio Deal
The deal, focused on a preclinical candidate and worth more than $1bn, follows DualityBio’s licensing agreement in April with BioNTech, amid growing interest among drug makers in ADCs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.